Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Ginès, RW. Schrier.
Hepatorenal syndrome and renal dysfunction associated with liver disease.
Diseases of the Kidney, 7th ed., pp. 2099-2127
[2.]
J. Post, A.J. Patek Jr.
Serum proteins in cirrhosis of the liver. Relation to prognosis and formation of ascites.
Arch Intern Med, 69 (1942), pp. 67-82
[3.]
H. Mankin, A. Lowell.
Osmotic factors influencing the formation of ascites in patients with cirrhosis of the liver.
J Clin Invest, 27 (1948), pp. 145-155
[4.]
M.H. Witte, C.L. Witte, A.E. Dumont.
Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites.
Gastroenterology, 61 (1971), pp. 740-742
[5.]
R. Hecker, S. Sherlock.
Electrolyte and circulatory changes in terminal liver failure.
Lancet, 2 (1956), pp. 1121-1125
[6.]
W.H. Abelman.
Hyperdynamic circulation in cirrhosis: a historical perspective.
Hepatology, 20 (1994), pp. 1356-1358
[7.]
V. Arroyo, P. Ginès, A.L. Gerbes, F.J. Dudley, P. Gentilini, G. Laffi, et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
Hepatology, 23 (1996), pp. 164-176
[8.]
B.A. Runyon.
Historical aspects of treatment of patients with cirrhosis and ascites.
Semin Liver Dis, 17 (1997), pp. 163-175
[9.]
A.J. Patek Jr, H. Mankin, H. Colcher, A. Lowell, D.P. Earle.
The effects of intravenous injection of concentrated human serum albumin upon blood plasma, ascites and renal function in three patients with cirrhosis of the liver.
J Clin Invest, 27 (1948), pp. 135-144
[10.]
W.W. Faloon, R.D. Eckhardt, A.M. Cooper, C.S. Davidson.
The effect of human serum albumin, mercurial diuretics, and a low sodium excretion in patients with cirrhosis of the liver.
J Clin Invest, 28 (1949), pp. 583-594
[11.]
P. Wilkinson, S. Sherlock.
The effect of repeated albumin infusions in patients with cirrhosis.
Lancet, ii (1962), pp. 1125-1129
[12.]
R.M. McCloy, W.P. Baldus, F.T. Maher, W.H.J. Summerskill.
Effects of changing plasma volume, serum albumin concentration, and plasma osmolality on renal function in cirrhosis.
Gastroenterology, 53 (1967), pp. 229-239
[13.]
P.Y. Wong, R.E. Carroll, T.L. Lipinsky, R.R. Capone.
Studies on the renin-angiotensin-aldosterone system in patients with cirrhosis and ascites: effect of saline and albumin infusion.
Gastroenterology, 77 (1979), pp. 1171-1176
[14.]
P. Angeli, G. Albino, P. Carraro, M. Dalla Pria, C. Merkel, L. Caregaro, et al.
Cirrhosis and muscle cramps: evidence of a causal relationship.
Hepatology, 23 (1996), pp. 264-273
[15.]
V. Arroyo, P. Sort, P. Ginès, R. Planas.
Treatment of ascites by paracentesis.
Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis and treatment, pp. 463-479
[16.]
P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, L. Ruiz del Árbol, et al.
Effect of intravenous albumin infusion prevents on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med, 341 (1999), pp. 403-409
[17.]
J. Uriz, P. Ginès, A. Cárdenas, P. Sort, W. Jiménez, J.M. Salmeron, et al.
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
J Hepatol, 33 (2001), pp. 43-48
[18.]
P. Ginès, T. Berl, M. Bernardi, D.A. Bichet, G. Hamon, W. Jiménez, et al.
Hyponatremia in cirrhosis: from pathogenesis to treatment.
Hepatology, 28 (1998), pp. 851-864
[19.]
R.W. Schrier, V. Arroyo, M. Bernardi, M. Epstein, J.H. Henriksen, J. Rodés.
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology, 8 (1988), pp. 1151-1157
[20.]
R.W. Schrier, M. Neiderbeger, A. Weigert, P. Ginès.
Peripheral arterial vasodilation: determinant of functional spectrum of cirrhosis.
Semin Liver Dis, 14 (1994), pp. 14-22
[21.]
P. Ginès, M. Guevara, V. Arroyo, J. Rodés.
Hepatorenal syndrome.
Lancet, 362 (2003), pp. 1819-1827
[22.]
J.H. Henriksen, S. Moller, S. Schifter, F. Bendtsen.
Increased arterial compliance in decompensated cirrhosis.
J Hepatol, 31 (1999), pp. 712-718
[23.]
V. Andreu, A. Perello, E. Moitinho, A. Escorsell, J.C. García-Pagán, J. Bosch, et al.
Total effective vascular compliance in patients with cirrhosis. Effects of propranolol.
J Hepatol, 36 (2002), pp. 356-361
[24.]
P.Y. Martin, P. Ginès, R.W. Schrier.
Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.
N Engl J Med, 339 (1998), pp. 533-541
[25.]
J. Bosch, J.C. García-Pagán.
The splanchnic circulation in cirrhosis.
Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis and treatment, pp. 330-350
[26.]
M. Fernández, R.W. Lambrecht, H.L. Bonkovsky.
Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity.
J Hepatol, 34 (2001), pp. 812-817
[27.]
N.R. Harris, N. Granger.
Alterations of hepatic and splanchnic microvascular exchange in cirrhosis: local factors in the formation of ascites.
Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis and treatment, pp. 351-364
[28.]
V. Arroyo, P. Ginès, R. Planas, J. Rodés.
Pathogenesis, diagnosis and treatment of ascites in cirrhosis.
Oxford Textbook of Clinical Hepatology, pp. 733-764
[29.]
V. Arroyo, R. Bataller, M. Guevara.
Treatment of hepatorenal syndrome.
Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis and treatment, pp. 492-510
[30.]
M. Guevara, P. Ginès, G. Fernández-Esparrach, P. Sort, W. Jiménez, V. Arroyo, et al.
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Hepatology, 27 (1998), pp. 35-41
[31.]
V. Gülberg, M. Bilzer, A.L. Gerbes.
Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine.
Hepatology, 30 (1999), pp. 870-875
[32.]
J.P. Mulkay, H. Louis, V. Donckier, N. Bourgeois, M. Adler, J. Deviere.
Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
Acta Gastroenterol Belg, 64 (2001), pp. 15-19
[33.]
R. Moreau, F. Durand, T. Poynard, C. Duhamel, J.P. Cervoni, P. Ichai, et al.
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective study.
Gastroenterology, 122 (2002), pp. 923-930
[34.]
R. Ortega, P. Ginès, J. Uriz, A. Cárdenas, B. Calahorra, D. De las Heras, et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Efficacy and outcome.
Hepatology, 36 (2002), pp. 941-948
[35.]
P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Roner, R. Merenda, et al.
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Hepatology, 29 (1999), pp. 1690-1697
[36.]
C. Duvoux, D. Zanditenas, C. Hézode, A. Chauvat, J.L. Monin, F. Thoural, et al.
Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study.
Hepatology, 36 (2002), pp. 374-380
[37.]
E.A. Pomfret, J.J. Pomposelli, R.L. Jenkins.
Live donor liver transplantation.
J Hepatol, 34 (2001), pp. 613-624
[38.]
S. Moller, F. Bendtsen, J.H. Henriksen.
Effects of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis.
Gastroenterology, 109 (1995), pp. 1917-1925
[39.]
S. Moller, E.F. Hansen, U. Becker, K. Brinch, J.H. Henriksen, F. Bendtsen.
Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients.
Liver, 20 (2000), pp. 51-59
Parte de los estudios descritos en esta revisión y realizados en la unidad de los autores han sido financiados con las siguientes ayudas: Marato Fundació TV3 (U-2000-TV2710), Fondo de Investigaciones Sanitarias de la Seguridad Social (FISS 00/0618 y 02/0701), Dirección General de Investigación Científica y Técnica (SAF 2001/0300), Instituto Reina Sofía de Investigación Nefrológica e Instituto de Salud Carlos III (CO3/2).
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
